GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased ri

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk

First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan